Teva, Allergan complete $39 billion generics deal
NEW YORK — Teva Pharmaceutical Industries Ltd. has closed its acquisition of the Allergan plc generics business. The companies said Tuesday that under the deal, announced last July, Allergan receives $33.4 billion in cash and 100.3 million shares of Teva stock, valued at $5.4 billion based on the opening price of $53.39 for Teva shares
